Hypoplastic left heart syndrome is a type of congenital heart disease characterized by
underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if …

Rapid admission and acute interventional treatment combined with modern antithrombotic
pharmacologic therapy have improved outcomes in patients with ST elevation myocardial …

Background Left ventricular ejection fraction (LVEF) is a major determinant of long‐term
prognosis after ST‐segment elevation myocardial infarction (STEMI). STEMI patients with …

Background Heart failure following myocardial infarction is a common, disabling, and deadly
condition. Direct injection of autologous bone marrow mononuclear cells into the …

Stromal cell-derived factor 1-alpha (SDF) is a potent bone marrow chemokine capable of
recruiting circulating progenitor populations to injured tissue. SDF has known angiogenic …

Background Low‐level laser therapy (LLLT) has photobiostimulatory effects on stem cells
and may offer cardioprotection. This cell‐based therapy may compliment primary …

One out of every two men and one out of every three women greater than the age of 40 will
experience an acute myocardial infarction (AMI) at some time during their lifetime. As more …

Progress has been made into research on new therapies, mechanical and pharmacological
approaches and repair/regenerative cellular therapy to treat irreversible cardiovascular …

Background: Autologous cell therapy represents a novel treatment option for vascular
regeneration in different disease conditions, with experimental and clinical studies indicating …

Purpose Results on the clinical utility of cell therapy for ST-elevated myocardial infarction
(STEMI) are controversial. This study sought to analyze the efficacy of treatment with …